Serum beta-2-microglobulin, TNF-α and interleukins in myeloproliferative disorders

European Journal of Haematology

Volumn 63, Issue 1, 1999, Pages 19-25

  Bourantas, Konstantinos L ^a,c   Hatzimichael, Eleftheria Chr ^a   Makis, Alexandros Chr ^a   Chaidos, Aristidis ^a   Kapsali, Eleni D ^a   Tsiara, Stavroula ^a   Mavridis, Anestis ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b G HATZIKOSTA GENERAL HOSPITAL   (Greece)

^c Department of Haematology ^*  (Greece)

Author keywords

Beta 2 microglobulin; IL 10; IL 1 ; IL 1 ; IL 2; IL 6; Myeloproliferative disorders; sIL 2R; TNF

Indexed keywords

BETA 2 MICROGLOBULIN; CYTOKINE; INTERLEUKIN 1 DERIVATIVE; INTERLEUKIN 10; INTERLEUKIN 2 DERIVATIVE; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD LEVEL; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS;

EID: 0033047792     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1999.tb01845.x     Document Type: Article

References (43)

1. Mancini M, Diverio D, Alimena G, Mandelli F. Recent advances in biological and therapeutic aspects of myeloproliferative disorders. Curr Opin Hematol 1994;1:261-267.
2. Motoi T, Uchiyama T, Hori T, Itoh K, Uchino K, Ueda R. Elevated serum-soluble interleukin-2 receptor (Tac Antigen) levels in chronic myelogenous leukemia patients with blastic crisis. Blood 1989;74:1052-1057.
3. Creswell P, Springer T, Stromiger JL, Turner MJ, Grey HM, Kubo RT. Immunological identity of small subunit of HLA antigens and beta 2 microglobulin and its turnover on the cell membrane. Proc Natl Acad Sci USA 1974;71:2123-2127.
4. Teasdale C, Mander AM, Fiheld R, Keyser JW, Newcombi RG, Hugues LE. Serum beta-2-microglobulin in controls and cancer patients. Clin Chim Acta 1977;78:135-143.
5. Byrnier GM, Cohen RJ, Conrad ME. Microglobulinemia in renal failure. Nature (London) 1968;218:598-599.
6. Barte R, Risch B, Diem H, Mudel M, Fateh-Moghadam A. Bone marrow histology and serum b2 microglobulin in multiple myeloma. A new prognostic factor. Eur J Haematol 1989;51:88-98.
7. Moller P, Herrmann B, Moldenhauer G, Momburg F. Defective expression of MHC class I antigens is frequent in B-cell lymphomas of high grade malignancy. Int J Cancer 1987;40:32-39.
8. Norfolk DR, Child JA, Roberts BE, Forbes MA, Copper EH. Serum beta-2 microglobulin in disorders of myeloid proliferation. Acta Haematol 1983;69:361-368.
9. Bourantas KL, Mavridis A, Tsiara ST, Seferiadis K. Beta-2 microglobulin in chronic myelogenous leukemia: Preliminary results. J Exp Clin Cancer Res 1996;15:283-286.
10. Child JA, Kushwaha MR. Serum beta-2-microglobulin in lymphoproliferative and myeloproliferative diseases. Hematol Oncol 1984;2:391-401.
11. Rorr I. Essential Immunology. Oxford: Blackwell Science, 1997;179-182.
12. Le Bousse Kerdiles MC, Soyri M, Smadja-Joffe F, Praloran V, Jasmin C, Ziltener HJ. Enhanced hematopoietic growth factor production in an experimental myeloproliferative syndrome. Blood 1992;79:3179-3187.
13. Barber KE, Crosier PS, Purdie KJ, et al. Human interleukin 3: Effects on normal and leukemic cells. Growth Factors 1989;1:101-114.
14. Griffin JD, Rambaldi A, Vallenga E, Young DC, Ostapovicz D, Cannistra SA. Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. Blood 1987;70:1218-1221.
15. Sakai K, Hattori T, Matsuoka M, et al. Autocrine stimulation of interleukin-1 beta in acute myelogenous leukemia cells. J Exp Med 1987;166:1597-1599.
16. Wetzler M, Kurzrock R, Estrov Z, et al. Altered levels of interleukin-1a and interleukin-1b receptor antagonist in chronic myelogenous leukemia: Clinical and prognostic correlates. Blood 1994;84:3142-3147.
17. Estrov Z, Kuzrock R, Lowe DG, et al. Suppression of chronic myclogenous leukemia colony growth by IL-1 receptor antagonist and soluble IL-1 receptors: A novel application for inhibitors of IL-1 activity. Blood 1991;78:1476-1484.
18. Kurzrock R, Wetzler M, Estrov Z, Talpaz M. Interleukin-1 and its inhibitors: A biologic and therapeutic model for the role of growth regulatory factors in leukemias. Cytokines Mol Ther 1995;1:177-194.
19. Aguilar-Santelises M, Magnusson R, Svenson SB, et al. Expression of interleukin-1α, interleukin-1β and interleukin-6 in chronic B lymphocytic leukemia (B-CLL) cells from patients at different stages of disease progression. Clin Exp Immunol 1991;84:422-428.
20. Gangarossa S, Romano V, Munda SE, Sciotta A, Schiliro G. Low serum levels of interleukin-6 in children with post infective acute thrombocytopenic purpura. Eur J Haematol 1995;55:117-120.
21. Hollen CW, Henthorn J, Koziol JA, Burstein SA. Serum interleukin-6 levels in patients with thrombocytosis. Leuk Lymphoma 1992;8:235-241.
22. Nachbauer DM, Herold M, Maneschg A, Huber H. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: Correlation with disease activity and other prognostic parameters. Ann Hematol 1991;62:54-58.
23. Hollen CW, Henthorn J, Koziol JA, Burstein SA. Elevated serum interleukin-6 levels in patients with reactive thrombocytosis. Br J Haematol 1991;9:286-290.
24. Paul CC, Baumann MA. Impaired interleukin-2 production by T-lymphocytes in polycythemia vera. J Clin Lab Anal 1989;3:84-87.
25. Rupoli S, Montillo M, Salvi A, et al. The soluble IL-2 receptor in malignant hemopathies. Recenti Prog Med 1992;83:546-551.
26. Kawatani T, Endo A, Tajima F, Ool S, Kawasaki H. Clinical significance of serum soluble interleukin-2 receptor in chronic myeloproliferative disorders. Int J Hematol 1997;65:123-128.
27. Zoumbos N, Symeonidis A, Kourakli A, et al. Increased levels of soluble interleukin-2 receptors and tumor necrosis factor in serum of patients with myelodysplastic syndromes [letter]. Blood 1991;77:413-414.
28. Pawelec G, Rehbein A, Schlotz E, Da Silva P. Cellular immune responses to autologous chronic myelogenous leukemia cells in vitro. Cancer Immunol Immunother 1996;42:193-199.
29. Fluckiger AC, Durand I, Banchereau J. Interleukin-10 induces apoptotic cell death of B-chronic lymphocytic leukemia cells. J Exp Med 1994;179:91-99.
30. Freedman MH, Cohen A, Grunberger T, et al. Central role of tumor necrosis factor, GM-CSF and interleukin 1 in the pathogenesis of juvenile chronic myelogenous leukemia. Br J Hacmatol 1992;80:40-45.
31. Duncombe AS, Heslop HE, Turner M, et al. Tumor necrosis factor mediates autocrine growth inhibition in a chronic leukemia. J Immunol 1989;143:3828-3834.
32. Haznedaroglu IC, Ertenli, I, Ozcebe O, et al. Megakaryocyte related interleukins in reactive thrombocytosis versus autonomous thrombocythemia. Acta Haematol 1996;95:107-111.
33. Mainou-Flower T, Copplestone JA, Prentice AG. Effect of interleukins on the proliferation and survival of B-cell chronic leukemia cells. J Clin Pathol 1995;48:482-487.
34. Dalekos GN, Elisaf M, Papagalanis N, Tzallas C, Siamopoulos KC. Elevated interleukin-1β, in the circulation of patients with essential hypertension before any drug therapy: A pilot study. Eur J Clin Invest 1996;26:936-939.
35. Dalekos GN, Elisaf M, Bairaktari F, Tsolas D, Siamopoulos KC. Increased serum levels of interleukin-1a in the systemic circulation of patients with essential hypertension: Additional risk factors for atherogenesis in hypertensive patients. J Lab Clin Med 1997;129:300-308.
36. Tsatsoulis A, Vlachoyiannopoulos PG, Dalekos GN, Johnson EO, Moutsopoulos HM. Increased serum interleukin-1b during treatment of hyperthyroidism with antithyroid drugs. Eur J Clin Invest 1995;25:754 758.
37. Litam P, Swan F, Cabanillas F, et al. Prognostic value of serum b2-microglobulin in low-grade lymphoma. Ann Int Med 1991;114:855-860.
38. Campos L, Vu Van H, Ville D, Imbert C, et al. Serum beta-2-microglobulin in adult myeloid acute leukemias. Blut 1984;48:221-226.
39. Swan F, Ordonez N, Manning J, et al. Beta-2-microglobulin cell surface expression to the serum level [abstract]. Blood 1988;72:258a.
40. Dreazen D, Canaani E, Gale RP. Molecular biology of chronic myelogenous leukemia. Semin Haematol 1988;25:35-49.
41. Hanney CS, Kuribayashi K, Kezn DE, Gillis S. Interleukin-2 augments natural killer cell activity. Nature (London) 1981;291:335-338.
42. Waldmann TA. The multi-subunit interleukin-2-receptors. Annu Rev Biochem 1989;58:875-911.
43. Waldmann TA. The structure, function and expression of interleukin-2-receptors in normal and malignant lymphocytes. Science 1986;232:727-732.